Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086059 | 0.84 | NTRK1 (0.37) | EGLN2NTRK1GPR88HRH4HRH3 | |
| SCHEMBL7650649 | 0.81 | IDO1 (0.37) | NTRK1GPR88HRH4HRH3 | |
| SCHEMBL19788540 | 0.80 | HRH4 (0.32) | NTRK1GPR88HRH4HRH3 | |
| SCHEMBL7602678 | 0.79 | ACHE (0.34) | GPR88HRH4HRH3 | |
| SCHEMBL20121775 | 0.79 | HRH4 (0.31) | HRH4HRH3 | |
| SCHEMBL12364368 | 0.79 | NTRK1 (0.32) | NTRK1HRH4HRH3 | |
| SCHEMBL13031208 | 0.79 | MEN1 (0.31) | HRH4HRH3ESRRG | |
| SCHEMBL19400545 | 0.78 | HRH4 (0.35) | HRH4HRH3 | |
| SCHEMBL13453642 | 0.78 | SMPD1 (0.41) | HRH4HRH3 | |
| SCHEMBL26328680 | 0.77 | NTRK1 (0.38) | NTRK1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107673-A2 | CLEAVABLE DISULFIDE LINKERS AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-04-20 | — | — | US | disclosed |
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-05 | — | — | US | disclosed |
| US-11174281-B1 | Modified nucleotides and uses thereof | Singular Genomics Systems, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021216998-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | NUDT1, PNP, NT5C2 | EGLN2 1982/4885NTRK1 3787/4885GPR88 2726/4885 |
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | NUDT1, RNMT, ADAR | EGLN2 1983/4885NTRK1 4448/4885GPR88 3971/4885 |
| US-11174281-B1 | Modified nucleotides and uses thereof | NUDT1, RNMT, ADAR | EGLN2 1983/4885NTRK1 4448/4885GPR88 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.